HealthTech Nexus Closes Seed Round to Accelerate AI Platform Development
Funding will be deployed to expand Bio R&D and RegIntel platform capabilities, with a focus on expanding into China, Japan, and Southeast Asian markets.
HealthTech Nexus today announced the successful close of its seed funding round. The capital will be used to accelerate product development across the Bio R&D and RegIntel platforms, expand the engineering and scientific team, and deepen market penetration across Asia-Pacific. The round was led by leading life sciences and deep-tech investors.
Related Articles
RegIntel Platform Goes Live with Multi-Country Regulatory Filing Support
The RegIntel platform provides real-time regulatory intelligence for pharma companies navigating NMPA, PMDA, and HSA filings.
HealthTech Nexus Partners with Leading Singapore Biomedical Research Institute
Partnership will pilot the Bio R&D data platform for translational research, covering clinical data management and AI-assisted drug target identification.
Asia-Pacific Pharma Digitalization: 5 Trends Shaping 2026
From AI-accelerated regulatory submissions to GMP digital twins — we break down the key trends transforming life sciences operations across Asia.